Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Longeveron Allogeneic Human Mesenchymal Stem Cells in Aging Frailty (Japan Phase II)
jRCT2043200038Phase 2Suspended
- Sponsor
- Longeveron
- Start
- Nov 2022
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of allogeneic human mesenchymal stem cells in Fragility (3 arms), sponsored by Longeveron. Primary endpoint: Incidence of serious adverse events within 30 days. Started Nov 2022; status: suspended.
02
Drugs
allogeneic human mesenchymal stem cells
03
Conditions
Fragility
Beyond the preview
Go deeper on jRCT2043200038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2043200038.